
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) **February 22, 2006**



CHEMBIO DIAGNOSTIC, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of Incorporation)

0-30379
(Commission File Number)

88-0425691
(IRS Employer
Identification Number)

3661 Horseblock Road
Medford, NY 11763
(Address of principal executive
offices)
631-924-1135
(Registrant's Telephone Number)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01. Regulation FD Disclosures.

- (a) On February 22, 2006 the Registrant issued the press release titled “Chembio Appoints Distributor for its Rapid HIV Tests in Ethiopia” included herein as Exhibit 99.1.
- (b) On February 23, 2006 the Registrant issued the press release titled “Chembio’s Rapid HIV Test Selected by Nigeria” included herein as Exhibit 99.2.
- (c) On February 24, 2006 the Registrant issued the press release titled “Chembio to Present at the Wall Street Analysts Forum” included herein as Exhibit 99.3.

ITEM 9.01. Financial Statements and Exhibits

- (c) Exhibits.

99.1 [Press Release titled “Chembio Appoints Distributor for its Rapid HIV Tests in Ethiopia” issued February 22, 2006.](#)

99.2 [Press Release titled “Chembio’s Rapid HIV Test Selected by Nigeria” issued February 23, 2006.](#)

99.3 [Press Release titled “Chembio to Present at the Wall Street Analysts Forum” issued February 23, 2006.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 27, 2006

Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert

Lawrence A. Siebert

Chief Executive Officer



ChemBio Appoints Distributor for its Rapid HIV Tests in Ethiopia

MEDFORD, N.Y. - February 22, 2006 - ChemBio Diagnostics, Inc. (OTCBB: CEMI) has appointed Setema, Ltd. to distribute its rapid HIV tests in Ethiopia. Ethiopia has a population of over 73 million of which an estimated 1.5 million are infected with HIV. Under the auspices of the President's \$15 billion Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, TB and Malaria, the United States recently signed an agreement to provide Ethiopia with over \$84 million to prevent and treat HIV/AIDS. This will include a significant scale-up of rapid testing programs. ChemBio believes these programs are crucial in Ethiopia and other countries ravaged by the AIDS epidemic. Rapid tests effectively identify patients that may require anti-retroviral treatment. Ethiopia is currently evaluating rapid HIV tests including ChemBio's two HIV 1/2 STAT-PAK(TM) tests for possible inclusion in Ethiopia's testing protocol.

Setema is one of the largest medical device distributors in Ethiopia and the country's sole supplier of HIV viral load tests. Viral load tests monitor patients already identified with HIV (e.g., with a rapid test) to determine if and when they require anti-retroviral therapy.

Ethiopia is one of 50 countries worldwide that is part of the Clinton HIV/AIDS Initiative Procurement Consortium. ChemBio was recently selected by the Clinton HIV/AIDS Initiative ("CHAI") as one of four global suppliers of rapid HIV tests to these countries pursuant to the Memoranda of Understanding (MOU) CHAI has with them. For further information please visit www.clintonfoundation.org.

ABOUT CHEMBIO

ChemBio Diagnostics, Inc. (ChemBio) possesses expertise in the development and manufacturing of rapid test products for various infectious diseases, including HIV, Tuberculosis and Chagas Disease. References to ChemBio Diagnostics, Inc. may actually refer to ChemBio Diagnostic Systems, Inc.; the 100%-owned subsidiary of ChemBio Diagnostics, Inc. ChemBio is located at 3661 Horseblock Road, Medford, NY 11763. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to ChemBio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for ChemBio's products. ChemBio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in ChemBio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact ChemBio's success are more fully disclosed in ChemBio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact: Vince Daniels/James Carbonara
The Investor Relations Group 212-825-3210



ChemBio's Rapid HIV Test Selected by Nigeria

Projected Need for 35 Million Tests to Attain PEPFAR 2008 Goal

MEDFORD, N.Y. - February 23, 2006 - The Nigerian Ministry of Health announced this week that ChemBio Diagnostics, Inc.'s (OTCBB:CEMI) HIV 1/2 STAT-PAK(TM) is designated as a screening test in four out of the eight testing protocols that comprise Nigeria's Interim National Testing Algorithm. Nigeria is initially implementing a "parallel testing algorithm", and as such uses two screening tests from different manufacturers on each patient tested. This program is being launched very soon to quickly and accurately identify HIV positive individuals so that treatment goals can be achieved.

Nigeria is Africa's most populous country with an estimated 135 million inhabitants. It has an estimated 3.6 million HIV infected individuals of which only 28,500 are currently receiving anti-retroviral (ARV) treatment according to a recent report to Congress by PEPFAR, the acronym for President Bush's \$15 billion Emergency Plan for AIDS Relief. PEPFAR's goal is for 350,000 Nigerians to receive anti-retroviral treatment by 2008. Rapid HIV tests allow patients to be screened and confirmed at the point of care, and will help in Nigeria's efforts to scale up testing and thereby meet its treatment goals more rapidly. In addition to the PEPFAR targets, the Nigerian National AIDS Control Administration (NACA) is aiming to put 250,000 people on anti-retroviral viral treatment as soon as possible. ChemBio believes, based upon estimates by the Global Business Coalition on HIV/AIDS (www.businessfightsaids.org) and other experts that on average approximately 100 people need to be tested in order to identify one person eligible for treatment. This results in a projected need for 35 million patients to be tested (with at least one screening test) just to meet the goals established by PEPFAR for Nigeria.

"We are very pleased to be selected for Nigeria's Interim National Testing Algorithm. I believe that millions of individuals will need to be tested in order to identify HIV patients suitable for ARV treatment and to meet treatment targets," said Avi Pelossof, ChemBio's Vice President of Sales, Marketing and Business Development.

ChemBio is committed to supporting Nigeria's treatment goals with its rapid HIV tests. In late 2005, ChemBio established ChemBio Diagnostics Nigeria Ltd., a wholly owned subsidiary headed by Dr. Joseph Nnorom, MD, MPH. Dr. Nnorom was until most recently the Medical Epidemiologist of the U.S. CDC's Global AIDS Program in Nigeria, and has been working on HIV/AIDS in Nigeria for more than 20 years.

"We are proud to be associated with Nigeria's focused efforts to strengthen its response to the HIV/AIDS epidemic. Improved counseling and testing services will help Nigerians determine their serostatus and do something about it. Counseling and testing is as important to HIV prevention as it is to care and treatment", said Dr. Nnorom.

ABOUT CHEMBIO

ChemBio Diagnostics, Inc. (ChemBio) possesses expertise in the development and manufacturing of rapid test products for various infectious diseases, including HIV, Tuberculosis and Chagas Disease. References to ChemBio Diagnostics, Inc. may actually refer to ChemBio Diagnostic Systems, Inc.; the 100%-owned subsidiary of ChemBio Diagnostics, Inc. ChemBio is located at 3661 Horseblock Road, Medford, NY 11763. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to ChemBio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for ChemBio's products. ChemBio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in ChemBio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact ChemBio's success are more fully disclosed in ChemBio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact: Vince Daniels/James Carbonara
The Investor Relations Group 212-825-3210



Chembio to Present at the Wall Street Analysts Forum

MEDFORD, N.Y. - February 24, 2006 - Chembio Diagnostics Inc.'s (OTCBB: CEMI) Chairman and President, Lawrence Siebert, will present at the 17th annual Wall Street Analysts Forum on Tuesday, February 28th at 10:20 AM (EST) at the Princeton Club of New York in midtown Manhattan. A live webcast of the presentation will be available on the Company's website at www.chembio.com. Additional information regarding the conference can be found at www.Analyst-conference.com.

Mr. Siebert will speak about the Company's development of their rapid diagnostic tests for infectious diseases. He will address the effect that government funding, treatment goals and HIV/AIDS initiatives are having towards the worldwide demand for rapid HIV diagnostic tests, as well as the status of their PMA application to the United States Food & Drug Administration for U.S. marketing approval. Chembio's rapid HIV tests include the HIV 1/2 STAT-PAK(TM), HIV 1/2 STAT-PAK Dipstick and the HIV 1/2 SURE CHECK(R). These tests are simple, safe and cost-effective requiring less than five microliters of blood from a fingerstick sample.

ABOUT CHEMBIO

Chembio Diagnostics, Inc. (OTCBB: CEMI) possesses expertise in the development and manufacturing of rapid diagnostic tests for various infectious diseases. Chembio is participating in the frontlines of the global battle against the devastating AIDS pandemic. This battle, to which the United States alone has pledged \$15 billion in international aid, is the impetus behind Chembio's rapid HIV tests. Because rapid tests can detect HIV antibodies within minutes, the massive prevention and treatment programs that are now scaling up can be much more effective. Chembio is one of four global rapid HIV test suppliers under the Clinton HIV/AIDS Initiative (www.clintonfoundation.org). The Company also manufactures additional rapid tests that it has developed for other deadly diseases, including human and veterinary Tuberculosis and Chagas Disease. References to Chembio Diagnostics, Inc. may actually refer to Chembio Diagnostic Systems, Inc.; the 100%-owned subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock Road, Medford, NY 11763. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact: Vince Daniels/James Carbonara
The Investor Relations Group 212-825-3210